Overall Survival and Progression-Free Survival of Patients Following Luspatercept Treatment in the MEDALIST Trial

被引：2

作者：

Santini, Valeria ^{[1
]}

Fenaux, Pierre ^{[2
]}

Zeidan, Amer M. ^{[3
,4
]}

Komrokji, Rami S. ^{[5
]}

Buckstein, Rena ^{[6
]}

Oliva, Esther Natalie ^{[7
]}

Ha, Xianwei ^{[8
]}

Miteva, Dimana ^{[9
]}

Yucel, Aylin ^{[8
]}

Nadal, Jose Alberto ^{[9
]}

Platzbecker, Uwe ^{[10
]}

机构：

[1] Univ Florence, Florence, Italy

[2] Hop St Louis, Assistance Publ Hop Paris AP HP, Paris, France

[3] Yale Univ, Yale Sch Med, New Haven, CT USA

[4] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[5] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[6] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada

[7] Grande Osped Metropolitano Bianchi Melacrino More, Reggio Di Calabria, Italy

[8] Bristol Myers Squibb, Princeton, NJ USA

[9] Bristol Myers Squibb Co, Celgene Int Sarl, Boudry, Switzerland

[10] Univ Leipzig, Med Ctr, Dept Hematol Cell Therapy & Hemostaseol, Leipzig, Germany

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-157489

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4079 / 4081

页数：3

共 50 条

[1] ANALYSIS OF THE CORRELATION OF TIME TO TREATMENT FAILURE WITH OVERALL SURVIVAL VERSUS CORRELATION OF PROGRESSION-FREE SURVIVAL WITH OVERALL SURVIVAL
Gibson, G. D.
Henegan, J. C.
JOURNAL OF INVESTIGATIVE MEDICINE, 2022, 70 (02) : 548 - 548
[2] Impact of Race on Progression-Free Survival and Overall Survival in Patients with Multiple Myeloma
Wani, Kashmira
Gutta, Radhika
Mittal, Aayush
Jamil, Maria
Springer, Kylie
Kuriakose, Philip
BLOOD, 2023, 142
[3] The validity of progression-free survival 2 as a surrogate trial end point for overall survival
Woodford, Rachel G.
Zhou, Deborah D. X.
Kok, Peey-Sei
Lord, Sally J.
Friedlander, Michael
Marschner, Ian C.
Simes, R. John
Lee, Chee Khoon
CANCER, 2022, 128 (07) : 1449 - 1457
[4] Concordance index: Surrogacy of progression-free survival for overall survival
Fan, Yiwei
Yin, Guosheng
CONTEMPORARY CLINICAL TRIALS, 2021, 104
[5] Progression-free survival (PFS) as a surrogate for overall survival (OS)
Stewart, David J.
Bosse, Dominick
Hilton, John
Goss, Glenwood
Fung-Kee-Fung, Michael
Jonker, Derek
CANCER RESEARCH, 2018, 78 (13)
[6] CORRECT trial: regorafenib significantly increases overall and progression-free survival
不详
COLORECTAL CANCER, 2012, 1 (04) : 283 - 283
[7] IS PROGRESSION-FREE SURVIVAL A GOOD INDICATOR OF OVERALL SURVIVAL FOR PAZOPANIB IN PATIENTS WITH SYNOVIAL SARCOMA?
Han, J.
Lee, S.
Cho, E.
VALUE IN HEALTH, 2022, 25 (12) : S489 - S490
[8] Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
Cicero, Giuseppe
De Luca, Rossella
Dieli, Francesco
ONCOTARGETS AND THERAPY, 2018, 11 : 3059 - 3063
[9] Modeling the Relationship between Progression-Free Survival and Overall Survival: The Phase II/III Trial
Redman, Mary W.
Goldman, Bryan H.
LeBlanc, Michael
Schott, Anne
Baker, Laurence H.
CLINICAL CANCER RESEARCH, 2013, 19 (10) : 2646 - 2656
[10] Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma
Ludwig, Heinz
Adam, Zdenek
Tothova, Elena
Hajek, Roman
Labar, Boris
Egyed, Miklos
Spicka, Ivan
Gisslinger, Heinz
Drach, Johannes
Kuhn, Ingrid
Hinke, Axel
Zojer, Niklas
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (09): : 1548 - 1554

← 1 2 3 4 5 →